Interferon-beta increases plasma ceramides of specific chain length in multiple sclerosis patients, unlike fingolimod or natalizumab

Interferon-beta increases plasma ceramides of specific chain length in multiple sclerosis patients, unlike fingolimod or natalizumab

Fingolimod is used for the treatment of multiple sclerosis (MS) and targets receptors for the bioactive sphingolipid sphingosine-1-phosphate. Whether fingolimod or other MS therapies conversely affect plasma concentrations of sphingolipids has, however, not yet been analyzed. Herein, we quantified 1...

Full description

Saved in:
Bibliographic Details
Main Authors: Florian Ottenlinger (Author), Christoph Alexander Mayer (Author), Nerea Ferreirós (Author), Yannick Schreiber (Author), Anja Schwiebs (Author), Katrin Schmidt (Author), Hanns Ackermann (Author), Josef Pfeilschifter (Author), Heinfried H. Radeke (Author)
Format: Book
Published: Frontiers Media S.A., 2016-11-01T00:00:00Z.
Subjects:
article
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

Connect to this object online.

3rd Floor Main Library

Holdings details from 3rd Floor Main Library
Call Number: A1234.567
Copy 1 Available

Similar Items